177lu-dotatate therapy in metastatic/ inoperable pheochromocytoma-paraganglioma
dc.contributor.author | Jaiswal, S. K. | |
dc.contributor.author | Sarathi, V. | |
dc.contributor.author | Memon, S. S. | |
dc.contributor.author | Malhotra, G. | |
dc.contributor.author | Verma, P. | |
dc.date.accessioned | 2021-01-13T06:36:52Z | |
dc.date.available | 2021-01-13T06:36:52Z | |
dc.date.issued | 2020 | |
dc.description.division | MD | en |
dc.format.extent | 4971 bytes | |
dc.format.mimetype | text/html | |
dc.identifier.source | Endocrine Connections, 2020. Vol. 9 (9): pp. 864-873 | en |
dc.identifier.uri | http://hdl.handle.net/123456789/21851 | |
dc.language.iso | en | en |
dc.subject | pheochromocytoma | en |
dc.subject | paraganglioma | en |
dc.subject | PRRT | en |
dc.subject | predictors of response | en |
dc.subject | SUVmax | en |
dc.title | 177lu-dotatate therapy in metastatic/ inoperable pheochromocytoma-paraganglioma | en |
dc.type | Article | en |